Published in Women's Health Weekly, May 26th, 2005
"Noven's strategy is to build upon our base hormone therapy (HT) business by introducing our patented transdermal technology into diverse therapeutic categories through collaborations with strong industry partners," said Robert C. Strauss, Noven's president, CEO and chairman. "With continued strong prescription demand for our Vivelle-Dot estrogen patch, and progress made toward commercialization of our partnered fentanyl and methylphenidate products, we are off to a good start in 2005."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly